Video Interview: Xbrane CEO On Biosimilar Lucentis
Executive Summary
The CEO of Stockholm-based Xbrane Biopharma Martin Åmark tells Sten Stovall that the complex generics specialist aims to be the first to sell a biosimilar version of Lucentis in Iran as part of its strategy to leverage patent gaps in emerging markets for high-priced drugs.